Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.

Cancer Med · 2014 · PMC4101749 · PMID 24574330

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.1140

boldest claim

The sentences

highly significantP < 0.0001actually significant

sEnd increases persisted through C2D22 and EOS (data not shown), and were found to be highly significant ( P < 0.0001; r -squared = 0.84).

also in 82,756 other papers

showed a trendP = 0.114not close (p > 0.1)

Soluble VEGF-R1 showed a trend for decreasing at C2D1 in 16 of 25 patients ( P = 0.114).

also in 33,481 other papers

did not reach statistical significanceno p-value reported

Although these changes did not reach statistical significance, they represent a strong trend.

also in 75,868 other papers

a statistical trendno p-value reported

A statistical trend was also seen for increases of VEGF-A and placenta growth factor (PlGF) at EOS.

also in 1,573 other papers

a strong trendno p-value reported

Signed-rank tests were used to determine statistical significance of biomarker changes, where P < 0.05 indicated significance; and 0.05 < P < 0.15 indicated a strong trend.

also in 3,373 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.